kabutan

Perseus Proteomics Inc.(4882) Summary

4882
TSE Growth
Perseus Proteomics Inc.
288
JPY
-8
(-2.70%)
Dec 12, 3:30 pm JST
1.84
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
289
Dec 12, 10:44 pm JST
Summary Chart Historical News Financial Result
PER
PBR
4.37
Yield
ー%
Margin Trading Ratio
816.02
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
294 JPY 1.89 USD
Previous Close Dec 11
296 JPY 1.89 USD
High Dec 12, 9:02 am
296 JPY 1.90 USD
Low Dec 12, 10:00 am
288 JPY 1.84 USD
Volume
177,200
Trading Value
0.05B JPY 0.33M USD
VWAP
289.91 JPY 1.86 USD
Minimum Trading Value
28,800 JPY 184 USD
Market Cap
4.25B JPY 0.03B USD
Number of Trades
247
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
Slightly High
1-Year Average
949
1-Year High Mar 21, 2025
12,283
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 0 1,930,800
Nov 28, 2025 0 1,905,200
Nov 21, 2025 0 1,994,300
Nov 14, 2025 1,400 2,031,700 1451.21
Nov 7, 2025 0 2,079,300
Company Profile
Perseus Proteomics Inc. is a biotech venture company specializing in the development of high-performance antibody drugs and research reagents targeting cancer.
Sector
Pharmaceuticals
Perseus Proteomics Inc. is a biotech venture company that leverages its academic drug discovery network originating from the University of Tokyo to conduct research and development of antibody drugs. Utilizing proprietary antibody acquisition and engineering technologies, the company is advancing the development of therapeutic antibodies targeting cancer and hematological diseases. Its main pipeline includes PPMX-T002, a radioisotope-labeled antibody targeting cadherin 3, and PPMX-T003, an antibody targeting transferrin receptor 1. The company's revenue is derived from upfront payments from out-licensing drug candidates to domestic and international pharmaceutical companies, milestone payments based on development progress, and royalty income as a percentage of sales after market launch.